Fate Therapeutics vs Lineage Cell Therapeutics
FATE and LCTX side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How FATE and LCTX compare
Lineage Cell Therapeutics is the larger company, worth 1.5 times as much as Fate Therapeutics ($231M against $153M).
Lineage Cell Therapeutics grew revenue faster over the last twelve months (0.18% versus −33.4% for Fate Therapeutics).
Lineage Cell Therapeutics keeps more of each dollar of sales as profit, with a net margin of 16.2% compared with −2620% at Fate Therapeutics.
Lineage Cell Therapeutics scores higher on the StockData Score (8 against 6 for Fate Therapeutics), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | FATE | LCTX |
|---|---|---|
| Size and price | ||
| Market cap | $153M | $231M |
| Share price | $1.28 | $0.915 |
| Change, 1 year | 23.1% | −52.6% |
| Change, 5 years | −97.7% | −60.1% |
| Beta (5Y) | 2.42 | 0.96 |
| Employees | 161 | 77 |
| StockData Score | ||
| Total score | 6 | 8 (better) |
| Valuation score | 1 (better) | 0 |
| Growth score | 0 | 0 |
| Performance score | 0 | 3 (better) |
| Health score | 5 | 5 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 32.3× | 21.3× (better) |
| P/B | 1.2× (better) | 3.4× |
| FCF yield | −69.7% | −11.4% (better) |
| Fair value | $1.10 | $0.620 |
| Margin of safety | −16.5% (better) | −47.6% |
| Growth | ||
| Revenue growth (TTM) | −33.4% | 0.18% (better) |
| Revenue growth, 5Y average | −26.7% | 51.5% (better) |
| Profitability | ||
| Operating margin | −2760% | −280% (better) |
| Net margin | −2620% | 16.2% (better) |
| FCF margin | −2249% | −244% (better) |
| Return on equity | −67.8% | 3.9% (better) |
| Return on invested capital | −1647% | −1395% (better) |
| Financial health | ||
| Debt / equity | 0.00 | 0.00 |
| Current ratio | 4.41 | 5.96 (better) |
| Altman Z-score | −9.92 | −2.87 (better) |
| Piotroski F-score | 3 | 4 (better) |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 59.9% | 46.1% |
| Held by insiders | 25.7% | 74.4% |
| Insider net buying, 12 months | −$336K | $24.4K (better) |
| Short interest, % of float | 11.2% | 37.7% |
Go deeper
- FATE stock overview
- FATE income statement
- FATE valuation and score
- LCTX stock overview
- LCTX income statement
- LCTX valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.